|
Market Closed -
Nasdaq
16:00:00 2026-02-26 EST
|
5-day change | 1st Jan Change | ||
| 72.82 USD | +0.03% |
|
-.--% | +0.96% |
| 09-16 | Pharma sector doubles down on AI to slash costs, timelines | RE |
| 08-20 | Pharma sector doubles down on AI amid hopes of slashing costs, timelines | RE |
Company Valuation: Avidity Biosciences, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 957.7 | 1,115 | 1,474 | 670.6 | 3,470 | 10,868 |
| Change | - | 16.4% | 32.27% | -54.52% | 417.36% | 213.25% |
| Enterprise Value (EV) 1 | 630.5 | 720.9 | 874.4 | 85.12 | 1,975 | 9,221 |
| Change | - | 14.35% | 21.29% | -90.27% | 2,220.11% | 366.91% |
| P/E | -12.5x | -8.34x | -6.65x | -3.11x | -10.1x | -14.5x |
| PBR | 3.13x | 2.98x | 2.68x | 1.43x | 2.45x | 6.46x |
| PEG | - | -0.2x | -0.4x | 0.2x | 16.16x | -0.2x |
| Capitalization / Revenue | 141x | 120x | 160x | 70.1x | 318x | 579x |
| EV / Revenue | 92.9x | 77.3x | 94.8x | 8.9x | 181x | 492x |
| EV / EBITDA | -14.4x | -6.14x | -4.93x | -0.36x | -5.25x | -12.4x |
| EV / EBIT | -14.2x | -6.11x | -4.89x | -0.36x | -5.21x | -12.4x |
| EV / FCF | -32.3x | -14.8x | -12.2x | -0.98x | -10x | -27x |
| FCF Yield | -3.09% | -6.74% | -8.21% | -102% | -10% | -3.7% |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | -2.048 | -2.849 | -3.336 | -2.907 | -2.888 | -4.972 |
| Distribution rate | - | - | - | - | - | - |
| Net sales 1 | 6.787 | 9.326 | 9.224 | 9.56 | 10.9 | 18.76 |
| EBITDA 1 | -43.9 | -117.4 | -177.5 | -233.5 | -376.2 | -741.8 |
| EBIT 1 | -44.28 | -118.1 | -178.9 | -235.6 | -378.9 | -745.9 |
| Net income 1 | -44.36 | -118 | -174 | -212.2 | -322.3 | -684.6 |
| Net Debt 1 | -327.2 | -393.8 | -600 | -585.5 | -1,495 | -1,648 |
| Reference price 2 | 25.52 | 23.77 | 22.19 | 9.05 | 29.08 | 72.13 |
| Nbr of stocks (in thousands) | 37,527 | 46,897 | 66,447 | 74,101 | 119,309 | 150,676 |
| Announcement Date | 3/15/21 | 3/1/22 | 2/28/23 | 2/28/24 | 2/27/25 | 2/23/26 |
1USD in Million2USD
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 11.3B | |
| 17.94x | 4.15x | 9.74x | 0.5% | 77.35B | |
| 20.38x | 4.36x | 13.55x | 2.41% | 59.58B | |
| -17.37x | 25.93x | -16.84x | -.--% | 58.14B | |
| 34.33x | 11.68x | 22.39x | -.--% | 47.62B | |
| 20.59x | 4.55x | 12.98x | 0.71% | 45.34B | |
| 35.23x | 3.53x | 13.23x | -.--% | 31.92B | |
| 55.67x | 3.54x | 27.46x | -.--% | 25.29B | |
| 61.85x | 6.58x | 39.07x | -.--% | 20.88B | |
| 23.03x | 4.95x | 12.88x | -.--% | 15.64B | |
| Average | 27.96x | 7.70x | 14.94x | 0.4% | 39.3B | |
| Weighted average by Cap. | 21.86x | 8.56x | 11.45x | 0.56% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- RNA Stock
- Valuation Avidity Biosciences, Inc.
Select your edition
All financial news and data tailored to specific country editions
